Plain-English translation of NCT07442006 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a combination of Empagliflozin, , and works better than another common three-drug combination for people with type 2 diabetes. Both groups will take three medications daily, and researchers will measure how well each combination controls blood sugar levels and reduces dangerous blood sugar swings throughout the day.
Many people with type 2 diabetes find that taking two medications together still doesn't keep their blood sugar stable enough. This study explores whether adding a third medication from a specific class might provide better control and reduce the unpredictable blood sugar fluctuations that can increase health risks.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take one of two medication combinations by mouth each day. The study involves multiple clinic visits at participating centers where your blood sugar control will be measured and your overall health will be monitored. The exact duration and number of visits would be confirmed when you speak with the study team, but expect regular check-ins to track how well the medication is working and watch for any side effects.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
South Korea
Phase
Post-approval monitoring
Sponsor
JW Pharmaceutical
Enrollment target
~178 participants
Started
October 2025
Primary completion
March 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Saemi Kang
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.